荃信生物-B11月7日斥资607.13万港元回购30.42万股

Core Viewpoint - Company announced a share buyback of 304,200 shares for a total cost of HKD 6.0713 million, indicating confidence in its financial position and future prospects [1] Group 1 - The buyback is scheduled for November 7, 2025, reflecting the company's strategic approach to enhance shareholder value [1] - The total number of shares repurchased is 304,200, which may positively impact the stock price by reducing the number of shares outstanding [1] - The total expenditure for the buyback amounts to HKD 6.0713 million, demonstrating the company's commitment to returning capital to shareholders [1]